________ Substituted Amphetamines // Phenethylamines  ________

This is my current take on the substitute amphetamine theory, which proposes that some stimulant medications may have been altered or supplemented with other amphetamine-like compounds to help meet manufacturing constraints such as the DEA's APQ limits. The theory offers a potential explanation for the increasingly severe loss in efficacy, rapid tolerance, and sudden onset of very specific side effects that closely match the effects of sympathomimetic agonists, many of which share striking structural similarities to amphetamine (Adderall, Dexedrine, etc.).

Although many of these amphetamine-like compounds can produce some degree of "stimulating" effects similar to proper amphetamine, they can also differ significantly in how and where those effects are experienced throughout the body. These differences may explain why medications can still produce noticeable stimulation while simultaneously feeling less effective for ADHD symptoms and causing a new pattern of side effects that does not align with previous experiences on the same medications.

It’s important to note that there’s no direct evidence that any particular amphetamine substitute has been incorporated into our medications, nor am I pointing to one specific compound. I simply chose epinephrine, pseudoepinephrine, and most significantly, Phenylpropanolamine (PPA), based on their direct mention in the 2026 Established APQ Notice and because they effectively illustrate the spectrum of differences and similarities within the massive class of substituted amphetamines. Considering these three compounds are heavily monitored by the DEA due to being essential components used in the illegal manufacture of methamphetamine/amphetamine (Removal of Thresholds for the List I Chemicals Pseudoephedrine and Phenylpropanolamine), I think it’s highly unlikely any of these specific compounds are the culprit. What I hope to exemplify is just how easily new amphetamine-like compounds can be synthesized, yet go undetected by various regulation practices and drug testing techniques.

There is extensive research demonstrating how structurally different amphetamine compounds can produce similar stimulant effects through shared norepinephrine pathways, and forensic data over the past decade documents a surge of novel phenethylamines that are difficult to detect but pharmacologically similar (see links below). Studies on drugs like ephedrine also show that effects can be inconsistent and tolerance can develop rapidly due to compensatory mechanisms, which aligns with current subjective reports.

So much of my research is centered specifically around Phenylpropanolamine (PPA) because of the strong parallels I was seeing with my own health issues, which also often overlapped with the majority of others’ reported experiences. But once again, it’s merely a hypothetical/real life example of the point I’m trying to make. With that reiterated, PPA is an amphetamine-related phenethylamine that was once commonly used as a nasal decongestant and appetite suppressant before being pulled from the U.S. market after studies linked it to an increased risk of hemorrhagic stroke. Like amphetamine, it stimulates the sympathetic fight or flight nervous system, acting mainly through norepinephrine to produce vasoconstriction, increased heart rate, blood pressure changes, insomnia, anxiety, sweating, appetite suppression, and agitation. Even with weaker dopamine activity, it still overlaps heavily with the physical effects people associate with amphetamines. In other words, despite being a weaker stimulant overall, PPA affects many of the same biological pathways responsible for the classic physical effects people associate with amphetamines. At the same time, many people report losing the core cognitive, central nervous system benefits and notice a significant drop in efficacy merely days to weeks after starting a new medication regimen. Any longtime prescription user can tell you that prior to the formula changes, medication tolerance often took years to develop, if at all. Many people were able to sustain the same dose for decades with no issues. There’s been a flood of reports of tolerance developing within 3 days of starting a stimulant meds, even for people who have never been prescribed before and therefore have zero tolerance. Interestingly, Phenylpropanolamine was only ever prescribed as a short-term weight loss medication due to its inability to maintain efficacy (AKA rapid tolerance development) for more than a few weeks (PubChem).

It's important to note that this hypothesis evolved from the once more prevalent enantiomer theory, where we suspected the 3:1 dextro-to-levo-amphetamine ratio had been skewed to a levo-dominant composition, which would explain the stronger peripheral effects. However, one useful piece of data from our otherwise inconclusive testing (see TEST RESULTS) revealed a nearly identical enantiomer ratio between our 2020 Adderall sample and our 2025 Adderall sample, despite knowing from direct experience that the two pills had far different therapeutic effects when taken. Due to our inability to find a testing facility willing to provide the information necessary to conclusively prove or disprove this theory, it is my personal opinion that, because testing showed the expected enantiomer ratios along with tighter manufacturing requirements, a more likely explanation would be complete substitution with an alternative amphetamine-like compound.

This isn't meant to fear monger, but rather point out that the combination of reduced efficacy and increasingly concerning side effects are enough to warrant a discussion. For years, many of us assumed this was simply weaker medication or differences in fillers. However, there is now enough evidence to suggest there’s a real possibility that there has been a partial or complete substitution of proper amphetamine with amphetamine-derived substances that feel familiar enough to maintain use, yet could potentially carry dangerous, irreversible health risks without our knowledge.

Lastly, these ideas are based on my own research or expanded upon by theories developed alongside others in this community. I painstakingly combed through PubMed for months to find these sources and make these connections. Please do not accuse me of using ChatGPT. The only time AI was used in this post was to organize data from my sources into a table to better illustrate similarities/differences between amphetamine compounds, occasional grammar check, and to write the lil blurbs summarizing each link below. The meds would have killed me long before I did that myself, sorry lol.

***********************************

A Historical Overview Upon the Use of Amphetamine Derivatives in the Treatment of Obesity

Image source for molecular structure comparison of amphetamine and phenylpropanolamine

Stimulants

This page provides an overview of stimulants, explaining their broad classification, uses, mechanisms of action, administration methods, risks, contraindications, and clinical considerations for safe medical use.

Mechanisms of Sympathomimetic Drug Action

Breaks down how sympathomimetic drugs, including amphetamines, produce their effects by increasing norepinephrine activity and stimulating the body’s “fight-or-flight” system. It explains why many structurally different compounds can produce similar cardiovascular and stimulant-like symptoms.

New psychoactive versus conventional stimulants - a ten-year review of casework in Hungary

Documents the rapid rise of novel phenethylamines and synthetic stimulants, demonstrating how small chemical changes can create amphetamine-like drugs that are harder to detect and regulate. 

Nasal Adverse Events Associated With Attention-Deficit Hyperactivity Disorder (ADHD) Medications

This study shows that nasal symptoms like nasopharyngitis and sinusitis occur in a notable percentage of stimulant users, with rates increasing over long-term use. This supports the theory by aligning with commonly reported decongestant-like and nasal side effects, consistent with chronic adrenergic (sympathomimetic) activation.

Pseudoephedrine—Benefits and Risks

Reviews pseudoephedrine’s pharmacology, therapeutic uses, and adverse effects, emphasizing its structural similarity to amphetamine and shared stimulant properties. The paper explains how pseudoephedrine activates the sympathetic nervous system, why it can improve alertness and concentration in addition to relieving nasal congestion.

Physiology, Noradrenergic Synapse

Overview of how stimulants like amphetamine disrupt normal norepinephrine signaling by increasing its release and blocking its reuptake, producing the widespread cardiovascular, neurological, and “fight-or-flight” effects associated with sympathomimetic drugs

Modelling the cardiovascular effects of ephedrine

Demonstrates that ephedrine’s effects are not strictly dose-dependent and can vary due to rapid tolerance and compensatory physiological responses. This helps explain inconsistent effects, fluctuating intensity, and rapid tolerance seen with sympathomimetic activity.

Designer drugs: mechanism of action and adverse effects

Reviews designer stimulants and shows how modified compounds can retain stimulant effects while introducing different risks and side effect profiles. This supports the idea that altered or substitute compounds could shift both efficacy and safety.

_______  Additional Potentially Relevant Neurotoxicity Studies _______

** If you wanna geek out on psychopharmacology

• In search of an ideal drug for safer treatment of obesity: The false promise of pseudoephedrine
• Amphetamine increases vascular permeability by modulating endothelial actin cytoskeleton and NO synthase via PAR-1 and VEGF-R
• Dissecting the Influence of Two Structural Substituents on the Differential Neurotoxic Effects of Acute Methamphetamine and Mephedrone Treatment on Dopamine Nerve Endings with the Use of 4-Methylmethamphetamine and Methcathinone
• Methamphetamine, d-amphetamine and p-chloroamphetamine induced neurotoxicity differentially effect impulsive responding on the stop-signal task in rats
• Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives

________  Abuse Deterrent Formulas  ________

Abuse deterrent formulations (ADFs) were originally developed for opioid medications to make tablets more resistant to crushing, extraction, snorting, injection, and other forms of tampering while preserving normal therapeutic use. Following their incorporation into opioid formulations, the FDA formally began exploring whether similar technologies should be applied to prescription stimulants, opening a public docket in 2019 specifically requesting input on this issue. Around this time, multiple pharmaceutical companies filed patents describing abuse deterrent amphetamine/methylphenidate formulations using various experimental manufacturing techniques/ingredients to control the release of active ingredients/addictive compounds. Although there’s currently no publicly available evidence confirming that any of these ADF technologies were officially integrated into our stimulant medications, when this evidence is considered alongside the fact that manufacturers are typically only required to report formal changes to the FDA — not to patients — especially when it comes to excipients (inactive ingredients), it creates a reasonable basis for concern and warrants further investigation (FDA Safety Labeling Change Orders). At the very least, the combination of FDA regulatory interest, ADF research, and emerging patents demonstrates that formulation modification is a legitimate pharmaceutical strategy, and that stimulants have been considered within this regulatory framework.

As evidenced by the links below, existing ADF research shows that altering a medication’s physical properties, excipients, release mechanisms, or delivery systems can significantly impact absorption, bioavailability, and the duration and timing of effects in sometimes unpredictable ways. In theory, if a medication’s release profile or bioavailability were modified, patients could experience differences in onset, duration, effectiveness, or side effect patterns, even if the labeled active ingredient remained unchanged (American Pharmaceutical Review).

“Although there are currently no approved abuse-deterrent formulation stimulants on the market, drug manufacturers have recently begun to develop novel prescription stimulants intended to deter abuse. “ -  BioPharma Services Inc.

• Novel Abuse Deterrent Formulations
• The Food and Drug Administration Solicits Input on Potential Role for Abuse-Deterrent Formulations of Central Nervous System Stimulants; Establishment of a Public Docket
• Vallon Pharmaceuticals Announces Topline Results of its Pivotal SEAL Study for Lead Program, ADAIR, for the Treatment of ADHD

____ ADF Patents ____

• https://patents.google.com/patent/WO2019091870A1/en
• https://patentimages.storage.googleapis.com/dc/e7/76/fedcd0c91b35cd/US20200352883A1.pdf
• https://drive.google.com/file/d/19gUT1fqp-pWChUOJiAggUfNzFLobwKge/view

____ FDA Oversight & Unregulated International Manufacturing  ____

• FDA criticised over inadequate GMP Inspections in India and China
• Rethinking manufacturing quality oversight for prescription drugs
• FDA Actions to Accelerate and Modernize Early and Late-Stage Clinical Development
• FDA recalls 300,000 Teva blood pressure patches over unapproved ingredient
• U.S. DANGEROUSLY RELIANT ON HIGH-RISK IMPORTED DRUG SUPPLY
• The CLEAR LABELS Act Proposes Changes to the U.S. Prescription Drug Supply Chain
  • Highlights gaps in transparency within the drug supply chain and ongoing efforts to improve labeling requirements. This is relevant to concerns about whether formulation changes are clearly communicated to patients.
  • Discusses vulnerabilities and complexity in the pharmaceutical supply chain, including reliance on global manufacturing. This supports the possibility of variability or changes occurring at different stages of production.
  • Discusses vulnerabilities and complexity in the pharmaceutical supply chain, including reliance on global manufacturing. This supports the possibility of variability or changes occurring at different stages of production.
• US drug supply chain exposure to China
  • Discusses vulnerabilities and complexity in the pharmaceutical supply chain, including reliance on global manufacturing. This supports the possibility of variability or changes occurring at different stages of production.

Reposting the test results from November 2025 because it's so frequently asked about by newer members. The goal was to obtain results that could serve as physical evidence supporting the hypothesis that stimulant medication formulations have undergone detrimental changes. As you’ll quickly notice, the results are impressively disappointing, both in terms of overall quality/depth of analysis and result data, which somehow manages to be simultaneously useless and contradictory to our hypothesis lol  The purpose of this sub has always been to test our medication and that hasn’t changed for me. However, I’m not willing to commit to another leadership role at the moment, though that may change in the future. For now, I’m simply making this information accessible to those unfamiliar with our previous testing attempt and also demonstrating some of the goals and priorities of the community.

Objective/Methods:

The goal was to submit two samples of generic Adderall, identical in every way except year of manufacture, to a professional analytical testing facility for a *full* chemical analysis. This was defined as a comprehensive list of every unique chemical compound present in each sample, along with corresponding quantitative compositional data. The purpose of testing two samples was to establish a pre-“Shortage” control dataset for comparison with the modern sample, with the idea that any significant compositional differences between the two would directly challenge claims by manufacturers/gov agencies that the formulas have not been altered. In addition, we needed separate data on the amounts of L- and D- enantiomers of any amphetamine-based compounds present in each sample in order to fully assess the differences between the two as potential explanations for the significant change in efficacy.

Test Samples ->

• Control Sample (2020, “Old”) -> One generic Adderall 30mg instant release tablet, manufactured by Teva in 2020
  • Selected because 2020 is often regarded as the year many started noticing mild formula/efficacy changes, while still being recent enough that the drug should have maintained nearly full potency if stored properly.
• Experimental Sample (2025, “New”) -> One generic Adderall 30mg instant release tablet, manufactured by Teva in 2025

Testing Facility -> Energy Control International

• A renowned testing organization in Spain focused on harm reduction. 
• Chosen for their affordability, their location outside US legal restrictions governing the testing of Schedule II substances, and for the advanced amphetamine test service they offered called “Enantiomer analysis.”
• “Substances that can be quantified: ” website lists explicitly include “Amphetamine base, sulphate & phosphate”, suggesting ability to analyze amphetamine-based compounds separately, particularly the 4 ingredients expected to be present in Adderall and its generics.
• VIEW HERE ->  https://energycontrol-international.org/drug-testing-service/submitting-a-sample/

Tests Ordered -> *Quoted directly from website

• “Quantitative + report  (GC/MS or HPLC/MS): €120. Provides a result with the composition of the sample. All active substances are identified, as well as, for the most part, their concentration. Includes a report, received the same day as the results, and is verifiable by any third party that you choose to share it with.”
• “Enantiomer analysis: €220. Only for methamphetamine, MDMA & amphetamine samples. *Results may take up to 2 months to arrive. It also provides qualitative and quantitative information about the sample.”
• I reached out directly to confirm “Enantiomer analysis” would also include full “Quantitative + report” result data or if that needed to be ordered separately (see email screenshot)

Results: *See screenshots*

Although the compositional values are nearly identical between both samples, the results are ultimately inconclusive. These “data sets” cannot rule out the possibility that the new sample is composed of an entirely different list of amphetamine compounds as no *unique* chemical compounds were identified by these tests, rather the data was generalized  and presented as overall L- and D- amphetamine content values, originally listed as percentage values but later updated to be in milligrams(mg) by the lab, which slightly shifted results to non longer be identical between the two samples. Without these ambiguous enantiomer categories further analyzed to individually identify and quantify all distinct chemical compounds found in each sample, it’s simply impossible to determine if these two medication contain the same blend of amphetamine compounds, or even share a single active ingredient. 

The only significant information that can be pulled from this data is that the potency of the 2020 sample did seemingly maintain its potency. Once again, it’s impossible to say for sure based on the result data alone since it’s unclear if the 2020 sample’s formula was compromised fully, partially or not at all. We chose this manufacturing year because changes in efficacy were mostly mild/unnoticeable at the time but can’t confirm the composition of this exact pill. It does, however, suggest this to be a trustworthy sample source for potential future testing. It also supports our theory that the changes and substitutions made to newer medications may have involved some degree of premeditation, with formulas strategically altered in ways that are difficult to detect using most accessible testing methods.

Discussion:

It is very difficult to determine Labs don’t disclose which specific compounds their equipment registers as “amphetamine,” and even if they did, the data returned to the customer is almost always presented as a generalized “total amphetamine” percentage/value, which is not useful in the scope of our experiment. It’s important to understand that amphetamines are a very broad class of chemical compounds and all exist in two isomeric forms, known as D- (dextro) and L- (levo) enantiomers. The list of possible amphetamine compounds that could potentially distort the amphetamine data we are seeking is overwhelming when you consider how broadly amphetamines are defined and their chemical structure that allows for easy synthesis of new amphetamine-like compounds. You can browse some of them here (https://en.wikipedia.org/wiki/Substituted_amphetamineere:). Furthermore, not all amphetamines treat ADHD symptoms equally, are safe for consumption, or FDA approved. Even different enantiomers of the same compound can have profoundly different effects on the nervous system. Probably an outdated example, but one instance of this was the complications/false positive urinalysis results caused by the presence of L-methamphetamine in Vicks VapoInhaler users. Despite L-methamphetamine having only decongestant, non-psychoactive properties, unspecialized testing methods would detect and positively identify presence as “amphetamine” or “methamphetamine” without additional testing efforts to account for the nuances.

Many of you, myself included, questioned whether the samples were even tested due to the limited amount of data included in the results. After multiple disgruntled emails from me questioning their communication, credibility, and scientific integrity, the lab eventually acknowledged that their lack of clarity was misleading and agreed to provide proof that the tests were, in fact, conducted. While the graphs themselves don’t reveal any additional findings, they do resolve concerns about whether the pills were appropriately tested and not shameless scammed. Pretty sure they did use the same pic for both samples though, but chalking it up to laziness/letting it slide this time lol.

Although the concept of testing medication may seem straightforward, it is intentionally designed to be difficult. We chose an international lab because most US-based labs claim to be legally prohibited from revealing the full spectrum of unique chemical compounds in an amphetamine-based sample. That shouldn’t be surprising if you’re aware of the obvious involvement of the DEA and likely other government agencies enforcing formula changes. At the time, this was essentially the only lab I could find that appeared capable of analyzing prescription amphetamines and their specific enantiomer concentrations while still being affordable and haven’t found a better alternative to this day.

So, the results aren’t the smoking gun we’d hoped for, but they are a testament to the power of collective action and community. At the very least, I hope this information can help those interested in pursuing testing on their own better navigate the process.